

# Patrizia Perri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8396623/publications.pdf>

Version: 2024-02-01

58  
papers

2,990  
citations

236612

25  
h-index

189595

50  
g-index

58  
all docs

58  
docs citations

58  
times ranked

4857  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of ALK as a major familial neuroblastoma predisposition gene. <i>Nature</i> , 2008, 455, 930-935.	13.7	1,207
2	Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. <i>Science Translational Medicine</i> , 2015, 7, 283ra55.	5.8	120
3	Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1953.	1.8	117
4	MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.. <i>Journal of Clinical Oncology</i> , 1997, 15, 85-93.	0.8	111
5	A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects. <i>Journal of Controlled Release</i> , 2016, 223, 165-177.	4.8	89
6	Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. <i>Journal of Controlled Release</i> , 2010, 145, 66-73.	4.8	78
7	Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis. <i>Clinical Cancer Research</i> , 2007, 13, 3977-3988.	3.2	77
8	Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma. <i>Cancer Research</i> , 2010, 70, 9816-9826.	0.4	65
9	A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. <i>Molecular Therapy</i> , 2017, 25, 218-231.	3.7	65
10	Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. <i>Molecular Therapy</i> , 2011, 19, 2201-2212.	3.7	57
11	Neuroblastoma-targeted Nanoparticles Entrapping siRNA Specifically Knockdown ALK. <i>Molecular Therapy</i> , 2011, 19, 1131-1140.	3.7	56
12	Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. <i>Journal of Controlled Release</i> , 2015, 211, 44-52.	4.8	49
13	Recent advances in the developmental origin of neuroblastoma: an overview. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 92.	3.5	46
14	PHOX2B mutations and genetic predisposition to neuroblastoma. <i>Oncogene</i> , 2005, 24, 3050-3053.	2.6	45
15	ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. <i>Cancer Research</i> , 2014, 74, 6094-6106.	0.4	45
16	The use of the orthotopic model to validate anti-vascular therapies for cancer. <i>International Journal of Developmental Biology</i> , 2011, 55, 547-555.	0.3	43
17	Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. <i>Journal of Controlled Release</i> , 2013, 170, 445-451.	4.8	41
18	Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. <i>Journal of Controlled Release</i> , 2019, 308, 44-56.	4.8	41

#	ARTICLE	IF	CITATIONS
19	Weak linkage at 4p16 to predisposition for human neuroblastoma. <i>Oncogene</i> , 2002, 21, 8356-8360.	2.6	40
20	PHOX2B-Mediated Regulation of ALK Expression: In Vitro Identification of a Functional Relationship between Two Genes Involved in Neuroblastoma. <i>PLoS ONE</i> , 2010, 5, e13108.	1.1	40
21	Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells. <i>Journal of Pathology</i> , 2005, 207, 346-357.	2.1	36
22	Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. <i>Biomaterials</i> , 2015, 68, 89-99.	5.7	36
23	Genetic Predisposition to Familial Neuroblastoma: Identification of Two Novel Genomic Regions at 2p and 12p. <i>Human Heredity</i> , 2007, 63, 205-211.	0.4	34
24	Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers. <i>Small</i> , 2019, 15, e1804591.	5.2	34
25	Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity. <i>European Journal of Cancer</i> , 2013, 49, 3353-3365.	1.3	32
26	Combined Replenishment of miR-34a and let-7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models. <i>Small</i> , 2020, 16, e1906426.	5.2	27
27	Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 180.	3.5	27
28	Quiescent Hepatic Stellate Cells Functionally Contribute to the Hepatic Innate Immune Response via TLR3. <i>PLoS ONE</i> , 2014, 9, e83391.	1.1	26
29	sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib. <i>Journal of Controlled Release</i> , 2014, 192, 157-166.	4.8	26
30	Familial neuroblastoma: a complex heritable disease. <i>Cancer Letters</i> , 2003, 197, 41-45.	3.2	24
31	Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles. <i>Small</i> , 2018, 14, e1802886.	5.2	23
32	Nanocarrier-Mediated Targeting of Tumor and Tumor Vascular Cells Improves Uptake and Penetration of Drugs into Neuroblastoma. <i>Frontiers in Oncology</i> , 2013, 3, 190.	1.3	21
33	New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against <i>ALK</i> . <i>Oncotarget</i> , 2015, 6, 28774-28789.	0.8	18
34	Linkage Analysis in Families with Recurrent Neuroblastoma. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 74-84.	1.8	17
35	Cotargeting of miR-126 and miR-221 inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling. <i>Molecular Oncology</i> , 2021, 15, 2969-2988.	2.1	16
36	A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma. <i>Cancers</i> , 2021, 13, 5528.	1.7	16

#	ARTICLE	IF	CITATIONS
37	N-myc amplification and cell proliferation rate in human neuroblastoma. , 1997, 183, 339-344.		15
38	Oligogenic inheritance in neuroblastoma. Cancer Letters, 2005, 228, 65-69.	3.2	15
39	A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo. Journal of Hepatology, 2016, 65, 75-83.	1.8	15
40	The Olive Leaves Extract Has Anti-Tumor Effects against Neuroblastoma through Inhibition of Cell Proliferation and Induction of Apoptosis. Nutrients, 2021, 13, 2178.	1.7	15
41	Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model. Current Drug Targets, 2009, 10, 1021-1027.	1.0	14
42	Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition. Cancers, 2020, 12, 1468.	1.7	14
43	MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway. Pharmaceuticals, 2022, 15, 297.	1.7	10
44	PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma. International Journal of Oncology, 1992, 33, 985.	1.4	8
45	Concomitant DDX1 and MYCN gain in neuroblastoma. Cancer Letters, 2007, 256, 56-63.	3.2	8
46	Retinoids Delivery Systems in Cancer: Liposomal Fenretinide for Neuroectodermal-Derived Tumors. Pharmaceuticals, 2021, 14, 854.	1.7	8
47	Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma. Journal of Personalized Medicine, 2021, 11, 107.	1.1	7
48	Bone Marrow Environment in Metastatic Neuroblastoma. Cancers, 2021, 13, 2467.	1.7	5
49	Peculiar allelotype associated with susceptibility to neuroblastoma. , 1996, 17, 60-63.		4
50	Restriction fragment length polymorphism analysis reveals different allele frequency and a linkage disequilibrium at locus D1S94 in neuroblastoma patients. European Journal of Cancer, 1997, 33, 1949-1952.	1.3	3
51	Metastatic progression in infants diagnosed with stage 4S neuroblastoma. A study of the Italian Neuroblastoma Registry. Pediatric Blood and Cancer, 2021, 68, e28904.	0.8	3
52	Abstract 1453: MicroRNA replacement and RNAi-mediated silencing of ALK as combined targeted therapies for neuroblastoma. Cancer Research, 2014, 74, 1453-1453.	0.4	1
53	Abstract A130: Effects of a novel liposomal formulation of fenretinide on human neuroblastoma cell growth, apoptosis and angiogenesis. , 2009, , .		0
54	Abstract 2622: New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs againstALK. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 3844: A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects. , 2016, , .		0
56	Abstract 5130: Tumor-penetrating peptide-coated nanoparticles as a novel strategy for the targeted therapy of neuroblastoma. , 2017, , .		0
57	Abstract 3879: Enhancement of tumor penetration by drug-loaded nanoparticles: An innovative targeted strategy for neuroblastoma. , 2018, , .		0
58	Abstract A101: Nucleolin: A novel cell surface protein for neuroblastoma targeted therapy. , 2019, , .		0